GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CNBX Pharmaceuticals Inc (OTCPK:CNBX) » Definitions » Gross Margin %

CNBX Pharmaceuticals (CNBX Pharmaceuticals) Gross Margin % : 82.93% (As of Feb. 2024)


View and export this data going back to 2007. Start your Free Trial

What is CNBX Pharmaceuticals Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. CNBX Pharmaceuticals's Gross Profit for the three months ended in Feb. 2024 was $0.03 Mil. CNBX Pharmaceuticals's Revenue for the three months ended in Feb. 2024 was $0.04 Mil. Therefore, CNBX Pharmaceuticals's Gross Margin % for the quarter that ended in Feb. 2024 was 82.93%.


The historical rank and industry rank for CNBX Pharmaceuticals's Gross Margin % or its related term are showing as below:

CNBX' s Gross Margin % Range Over the Past 10 Years
Min: 0   Med: 0   Max: 98.7
Current: 98.7


During the past 13 years, the highest Gross Margin % of CNBX Pharmaceuticals was 98.70%. The lowest was 0.00%. And the median was 0.00%.

CNBX's Gross Margin % is ranked better than
97.3% of 741 companies
in the Biotechnology industry
Industry Median: 59.43 vs CNBX: 98.70

CNBX Pharmaceuticals had a gross margin of 82.93% for the quarter that ended in Feb. 2024 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for CNBX Pharmaceuticals was 0.00% per year.


CNBX Pharmaceuticals Gross Margin % Historical Data

The historical data trend for CNBX Pharmaceuticals's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CNBX Pharmaceuticals Gross Margin % Chart

CNBX Pharmaceuticals Annual Data
Trend Aug14 Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

CNBX Pharmaceuticals Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 82.93

Competitive Comparison of CNBX Pharmaceuticals's Gross Margin %

For the Biotechnology subindustry, CNBX Pharmaceuticals's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CNBX Pharmaceuticals's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CNBX Pharmaceuticals's Gross Margin % distribution charts can be found below:

* The bar in red indicates where CNBX Pharmaceuticals's Gross Margin % falls into.



CNBX Pharmaceuticals Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

CNBX Pharmaceuticals's Gross Margin for the fiscal year that ended in Aug. 2023 is calculated as

Gross Margin % (A: Aug. 2023 )=Gross Profit (A: Aug. 2023 ) / Revenue (A: Aug. 2023 )
=0.4 / 0.41
=(Revenue - Cost of Goods Sold) / Revenue
=(0.41 - 0) / 0.41
=N/A %

CNBX Pharmaceuticals's Gross Margin for the quarter that ended in Feb. 2024 is calculated as


Gross Margin % (Q: Feb. 2024 )=Gross Profit (Q: Feb. 2024 ) / Revenue (Q: Feb. 2024 )
=0 / 0.041
=(Revenue - Cost of Goods Sold) / Revenue
=(0.041 - 0.007) / 0.041
=82.93 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


CNBX Pharmaceuticals  (OTCPK:CNBX) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

CNBX Pharmaceuticals had a gross margin of 82.93% for the quarter that ended in Feb. 2024 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


CNBX Pharmaceuticals Gross Margin % Related Terms

Thank you for viewing the detailed overview of CNBX Pharmaceuticals's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


CNBX Pharmaceuticals (CNBX Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
No. 3 Bethesda Metro Center, Suite 700, Bethesda, MD, USA, 20814
CNBX Pharmaceuticals Inc is a biotechnology company. It develops pharmaceuticals focusing on cancer research utilizing HTS technology and personalized bioinformatics tools. The company's main focus is the development of cannabinoid therapies and other technologies for the treatment of cancer, mainly cancers of the gastrointestinal tract, skin, breast, and prostate. The firm's main product is the RCC-33, an oral capsule for the treatment of colorectal cancer. The company tools include delivery systems, personalized medicine diagnostics, and therapies based on Cannabinoid compounds.
Executives
Cannabics Inc. 10 percent owner 108 WEST 13TH ST., WILMINGTON DE 19801
Thomas E Mills director, officer: President, CEO, CFO
North American Mining Corp 10 percent owner 6767 WEST TROPICANA AVENUE, SUITE 229, LAS VEGAS NV 89103
Lou Hilford director, officer: Vice-President, Secretary